John M Dye

List of Publications by Year
in descending order

111 papers	9,950 citations	44069 48 h-index	42399 92 g-index
125 all docs	125 docs citations	125 times ranked	13552 citing authors

#	Article	IF	Citations
1	Ebola virus entry requires the cholesterol transporter Niemannâ€“Pick C1. Nature, 2011, 477, 340-343.	27.8	1,127
2	Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science, 2020, 369, 731-736.	12.6	534
3	Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science, 2020, 369, 1261-1265.	12.6	520
4	Taxonomy of the order Mononegavirales: update 2016. Archives of Virology, 2016, 161, 2351-2360.	2.1	407
5	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Reports, 2022, 39, 110812.	6.4	287
6	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science, 2021, 371, 823-829.	12.6	285
7	Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO Journal, 2012, 31, 1947-1960.	7.8	284
8	Lassa virus entry requires a trigger-induced receptor switch. Science, 2014, 344, 1506-1510.	12.6	251
9	Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5034-5039.	7.1	246
10	Taxonomy of the order Mononegavirales: update 2019. Archives of Virology, 2019, 164, 1967-1980.	2.1	224
11	Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science, 2021, 372, 1108-1112.	12.6	210
12	2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2020, 165, 3023-3072.	2.1	184
13	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Cell Host and Microbe, 2018, 24, 221-233.e5.	11.0	182
14	A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. Cell Host and Microbe, 2020, 28, 486-496.e6.	11.0	178
15	Taxonomy of the order Mononegavirales: update 2017. Archives of Virology, 2017, 162, 2493-2504.	2.1	173
16	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	28.9	173
17	Convalescent plasma antiâ€“SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. Journal of Clinical Investigation, 2020, 130, 6728-6738.	8.2	172
18	A Serological Point-of-Care Test for the Detection of IgG Antibodies against Ebola Virus in Human Survivors. ACS Nano, 2018, 12, 63-73.	14.6	163

#	Article	IF	Citations
19	Taxonomy of the order Mononegavirales: update 2018. Archives of Virology, 2018, 163, 2283-2294.	2.1	153
20	Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell, 2017, 169, 878-890.e15.	28.9	145
21	The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Science Translational Medicine, 2022, 14, eabl8124.	12.4	143
22	A shared structural solution for neutralizing ebolaviruses. Nature Structural and Molecular Biology, 2011, 18, 1424-1427.	8.2	113
23	Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats. ELife, 2015, 4, .	6.0	110
24	NRP2 and CD63 Are Host Factors for Lujo Virus Cell Entry. Cell Host and Microbe, 2017, 22, 688-696.e5.	11.0	108
25	Identification and pathological characterization of persistent asymptomatic Ebola virus infection in rhesus monkeys. Nature Microbiology, 2017, 2, 17113.	13.3	104
26	Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell, 2017, 169, 891-904.e15.	28.9	103
27	A â€œTrojan horseâ€•bispecific-antibody strategy for broad protection against ebolaviruses. Science, 2016, 354, 350-354.	12.6	101
28	Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion. MBio, 2015, 6, e00801.	4.1	100
29	Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Archives of Virology, 2013, 158, 301-311.	2.1	99
30	Protection of Nonhuman Primates against Two Species of Ebola Virus Infection with a Single Complex Adenovirus Vector. Vaccine Journal, 2010, 17, 572-581.	3.1	94
31	Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. Journal of Virology, 2016, 90, 266-278.	3.4	92
32	Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Protects Nonhuman Primates from Intramuscular and Aerosol Challenge with Ebolavirus. Journal of Virology, 2013, 87, 4952-4964.	3.4	87
33	Discussions and decisions of the 2012â€"2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012â€"June 2013. Archives of Virology, 2014, 159, 821-830.	2.1	85
34	Protocadherin-1 is essential for cell entry by New World hantaviruses. Nature, 2018, 563, 559-563.	27.8	84
35	Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. Cell Host and Microbe, 2019, 25, 39-48.e5.	11.0	83
36	A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. Cell Host and Microbe, 2019, 25, 49-58.e5.	11.0	82

#	Article	IF	Citations
37	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. Cell Reports, 2016, 15, 1514-1526.	6.4	80
38	Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein. Journal of Virology, 2016, 90, 279-291.	3.4	72
39	Taxonomy of the order Mononegavirales: second update 2018. Archives of Virology, 2019, 164, 1233-1244.	2.1	70
40	Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus. Cell Reports, 2017, 19, 413-424.	6.4	66
41	Niemann-Pick C1 Is Essential for Ebolavirus Replication and Pathogenesis <i>In Vivo</i>. MBio, 2015, 6, e00565-15.	4.1	65
42	Structural Basis for Differential Neutralization of Ebolaviruses. Viruses, 2012, 4, 447-470.	3.3	63
43	2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2021, 166, 3513-3566.	2.1	62
44	Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Archives of Virology, 2014, 159, 1229-37.	2.1	59
45	Interferon Î±/Î² Receptorâ€“Deficient Mice as a Model for Ebola Virus Disease. Journal of Infectious Diseases, 2015, 212, S282-S294.	4.0	56
46	Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemannâ€“Pick C1. Virology, 2014, 468-470, 637-646.	2.4	55
47	Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Archives of Virology, 2013, 158, 1425-1432.	2.1	54
48	Homologous and Heterologous Protection of Nonhuman Primates by Ebola and Sudan Virus-Like Particles. PLoS ONE, 2015, 10, e0118881.	2.5	50
49	Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names. Viruses, 2014, 6, 3663-3682.	3.3	49
50	Novel Small Molecule Entry Inhibitors of Ebola Virus. Journal of Infectious Diseases, 2015, 212, S425-S434.	4.0	49
51	Profile and Persistence of the Virus-Specific Neutralizing Humoral Immune Response in Human Survivors of Sudan Ebolavirus (Gulu). Journal of Infectious Diseases, 2013, 208, 299-309.	4.0	47
52	Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates. Nature Communications, 2019, 10, 105.	12.8	45
53	Persistent Immune Responses after Ebola Virus Infection. New England Journal of Medicine, 2013, 369, 492-493.	27.0	44
54	Synthesis and Structureâ€“Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3-<i>b</i>]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity. Journal of Medicinal Chemistry, 2019, 62, 5810-5831.	6.4	44

#	Article	IF	Citations
55	Ebola Virus Genome Plasticity as a Marker of Its Passaging History: A Comparison of In Vitro Passaging to Non-Human Primate Infection. PLoS ONE, 2012, 7, e50316.	2.5	44
56	Toll-Like Receptor Agonist Augments Virus-Like Particle-Mediated Protection from Ebola Virus with Transient Immune Activation. PLoS ONE, 2014, 9, e89735.	2.5	43
57	Calcium Regulation of Hemorrhagic Fever Virus Budding: Mechanistic Implications for Host-Oriented Therapeutic Intervention. PLoS Pathogens, 2015, 11, e1005220.	4.7	42
58	Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses. Vaccine Journal, 2016, 23, 717-724.	3.1	40
59	Ebola Virus VP40 Modulates Cell Cycle and Biogenesis of Extracellular Vesicles. Journal of Infectious Diseases, 2018, 218, S365-S387.	4.0	40
60	Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Cell, 2021, 184, 3486-3501.e21.	28.9	39
61	Optimization of Isothiazolo[4,3-<i>b</i>]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity. Journal of Medicinal Chemistry, 2018, 61, 6178-6192.	6.4	36
62	Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. Scientific Reports, 2016, 6, 24897.	3.3	35
63	Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins. PLoS Pathogens, 2019, 15, e1008061.	4.7	35
64	A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. MBio, 2021, 12, e0247321.	4.1	35
65	Cysteine Cathepsin Inhibitors as Anti-Ebola Agents. ACS Infectious Diseases, 2016, 2, 173-179.	3.8	33
66	Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States. Transfusion, 2020, 60, 1024-1031.	1.6	32
67	Structural basis of broad ebolavirus neutralization by a human survivor antibody. Nature Structural and Molecular Biology, 2019, 26, 204-212.	8.2	30
68	Filovirius vaccines. Hum Vaccin, 2011, 7, 701-711.	2.4	29
69	Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design. Cell Host and Microbe, 2020, 27, 262-276.e4.	11.0	29
70	Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays. Methods, 2021, 195, 57-71.	3.8	29
71	Generation and characterization of protective antibodies to Marburg virus. MAbs, 2017, 9, 696-703.	5.2	28
72	Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38. Journal of Virology, 2020, 94, .	3.4	28

#	Article	IF	Citations
73	Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. International Journal of Biological Macromolecules, 2021, 183, 203-212.	7.5	28
74	Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. Scientific Reports, 2016, 6, 19193.	3.3	27
75	Extracellular Vesicles and Ebola Virus: A New Mechanism of Immune Evasion. Viruses, 2019, 11, 410.	3.3	27
76	Profiling the Native Specific Human Humoral Immune Response to Sudan Ebola Virus Strain Gulu by Chemiluminescence Enzyme-Linked Immunosorbent Assay. Vaccine Journal, 2012, 19, 1844-1852.	3.1	26
77	A Single Residue in Ebola Virus Receptor NPC1 Influences Cellular Host Range in Reptiles. MSphere, 2016, 1, .	2.9	25
78	Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses. PLoS ONE, 2015, 10, e0137786.	2.5	24
79	Synthetic Antibodies with a Human Framework That Protect Mice from Lethal Sudan Ebolavirus Challenge. ACS Chemical Biology, 2014, 9, 2263-2273.	3.4	23
80	Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease. Science Translational Medicine, 2017, 9, .	12.4	23
81	Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice. Journal of Virology, 2017, 91, .	3.4	23
82	Development of an antibody cocktail for treatment of Sudan virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3768-3778.	7.1	23
83	Euthanasia Assessment in Ebola Virus Infected Nonhuman Primates. Viruses, 2014, 6, 4666-4682.	3.3	22
84	Implementation of Objective PASC-Derived Taxon Demarcation Criteria for Official Classification of Filoviruses. Viruses, 2017, 9, 106.	3.3	22
85	The Ebola-Glycoprotein Modulates the Function of Natural Killer Cells. Frontiers in Immunology, 2018, 9, 1428.	4.8	22
86	Enhancement of Ebola virus infection by seminal amyloid fibrils. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7410-7415.	7.1	21
87	Immune Memory to Sudan Virus: Comparison between Two Separate Disease Outbreaks. Viruses, 2015, 7, 37-51.	3.3	20
88	Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate. Journal of Infectious Diseases, 2018, 218, S636-S648.	4.0	19
89	Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges). Viruses, 2016, 8, 94.	3.3	18
90	A novel compound active against SARS-CoV-2 targeting uridylate-specific endoribonuclease (NendoU/NSP15): <i>in silico</i> and <i>in vitro</i> investigations. RSC Medicinal Chemistry, 2021, 12, 1757-1764.	3.9	18

#	Article	IF	Citations
91	Possibility and Challenges of Conversion of Current Virus Species Names to Linnaean Binomials. Systematic Biology, 2016, 66, syw096.	5.6	17
92	Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail. Viruses, 2018, 10, 286.	3.3	16
93	Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses. Science Translational Medicine, 2022, 14, eabl5399.	12.4	16
94	Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. Journal of Experimental Medicine, 2017, 214, 2563-2572.	8.5	15
95	Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Bioorganic and Medicinal Chemistry, 2021, 47, 116393.	3.0	15
96	Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcÎ³RI. Scientific Reports, 2017, 7, 6054.	3.3	13
97	BIKE regulates dengue virus infection and is a cellular target for broad-spectrum antivirals. Antiviral Research, 2020, 184, 104966.	4.1	10
98	Toll-like receptor 4 mediates blood-brain barrier permeability and disease in C3H mice during Venezuelan equine encephalitis virus infection. Virulence, 2021, 12, 430-443.	4.4	10
99	Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors. Viruses, 2016, 8, 133.	3.3	8
100	Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins. Journal of Biological Chemistry, 2018, 293, 6201-6211.	3.4	7
101	Convalescent Plasma and the Dose of Ebola Virus Antibodies. New England Journal of Medicine, 2017, 376, 1296-1297.	27.0	6
102	Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. Journal of Virology, 2021, 95, .	3.4	6
103	Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity. Frontiers in Immunology, 2021, 12, 729851.	4.8	5
104	Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naÃ¯ve and Experienced Individuals. Viruses, 2022, 14, 370.	3.3	5
105	How to turn competitors into collaborators. Nature, 2017, 541, 283-285.	27.8	3
106	Characterization of an Anti-Ebola virus Hyperimmune Globulin Derived from Convalescent Plasma. Journal of Infectious Diseases, 2021, , .	4.0	3
107	Mechanistic and Fc requirements for inhibition of Sudan virus entry and in vivo protection by a synthetic antibody. Immunology Letters, 2017, 190, 289-295.	2.5	2
108	Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors. EBioMedicine, 2019, 46, 215-226.	6.1	2

#	Article	IF	Citations
109	On-Demand Patient-Specific Phenotype-to-Genotype Ebola Virus Characterization. Viruses, 2021, 13, 2010.	3.3	1
110	Neutralizing Antibodies against Crimeanâ€“Congo Hemorrhagic Fever Virus Derived from a Human Survivor. Proceedings (mdpi), 2020, 50, .	0.2	0
111	Mapping the Interface between New World Hantaviruses and Their Receptor, PCDH1. Proceedings (mdpi), 2020, 50, .	0.2	0